Clonidine Oral Liquid Buffer Composition for Stability and Taste
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral liquid formulations of clonidine lack stability and do not address the bitter taste, with many formulations lacking essential components like flavoring agents and having pH uncertainties, leading to unsuitable administration and potential degradation issues.
Innovation Solution
A ready-to-use oral liquid formulation comprising clonidine or its pharmaceutically acceptable salt, propylene glycol, one or more buffering agents, and pharmaceutically acceptable excipients, specifically using sodium dihydrogen phosphate and disodium hydrogen phosphate to maintain a pH of 6 to 8, ensuring stability and palatability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oral liquid formulations of clonidine are used, then the formulation can be administered orally, but the formulation lacks stability and has bitter taste
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the formulation to a specific range (pH 6.0-8.0) using buffering agents such as sodium dihydrogen phosphate and disodium hydrogen phosphate. This pH optimization simultaneously improves formulation stability and reduces the bitter taste of clonidine, resolving the technical contradiction between stability and palatability.
Solution Approach 2:
The patent introduces flavoring agents as intermediary substances that mask or counteract the bitter taste of clonidine. These flavoring agents act as mediators between the active ingredient and the patient's sensory system, improving palatability without affecting the stability or therapeutic efficacy of the formulation.
2Ease of manufacture
If existing oral liquid formulations are used, then the formulation can be prepared, but pH is uncertain and leads to degradation
Solution Approach 1:
The patent establishes specific parameter ranges for pH (6.0-8.0) and buffer concentration to ensure both ease of manufacture and formulation stability. By defining these critical parameters, the formulation can be reliably prepared while maintaining optimal stability conditions throughout storage.
Solution Approach 2:
The patent incorporates buffering agents that provide pH feedback control, automatically resisting pH changes that occur during storage or minor formulation variations. This feedback mechanism ensures pH remains within the optimal stability range without requiring complex manufacturing controls.
3Device complexity
If existing formulations without buffering agents are used, then the formulation is simpler, but long-term stability is compromised
Solution Approach 1:
The buffering agents in the formulation serve multiple functions simultaneously: they maintain pH stability for long-term storage, reduce the bitter taste of clonidine, and provide a foundation for flavoring agent effectiveness. This multi-functionality justifies the added complexity by resolving multiple technical issues with a single component.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a stable, ready-to-use solution with improved taste and long-term stability, suitable for direct administration without reconstitution, addressing the taste and stability issues of previous formulations.
Implementation Method 1
one or more buffering agents, specifically using sodium dihydrogen phosphate and disodium hydrogen phosphate to maintain a pH of 6 to 8
Implementation Method 2
A ready-to-use oral liquid formulation comprising clonidine or its pharmaceutically acceptable salt, propylene glycol
Data Source
AI summary
The present disclosure relates generally to a ready-to-use oral liquid formulation of clonidine or pharmaceutically acceptable salt thereof, as well as methods of manufacture and use.